GIANT PARTNERSHIP FROM JANSSEN AND ABDİ İBRAHİM PHARMACEUTICAL COMPANY

Janssen, a pharmaceutical company of Johnson & Johnson, has joined forces with the Turkish pharmaceutical company Abdi İbrahim. Within the scope of the partnership between Abdi İbrahim and Janssen, which has carried out about 40 million dollars of clinical research in our country in the last 10 years, it is aimed to increase domestic drug production capacity and competence.

In the ceremony organized for the signature of the partnership, the CEO of Janssen Emerging Markets, Luis Diaz Rubio, CEO of Janssen Turkey, Maria Fernando Prado and CEO Süha Taşpolatoğlu, representing Abdi İbrahim, participated.

Speaking at the ceremony, Janssen General Manager of Emerging Markets, Luis Diaz Rubio, said that Turkey is an important country in the region with its breakthroughs especially in the last 10 years and the treatments it provided. Rubio said: “We are one of the companies that invest the most in R&D. We spend more than 20 percent of our global annual income on R&D investments. With our strategy of reaching the needy of innovative medicines, as Johnson & Johnson’s pharmaceutical company Janssen, we have put 16 new molecules into the service of medicine since 2009. We maintain our trust and loyalty to the country with our 20 years of investments and innovative treatments in Turkey. We are engaged in initiatives that aim to advance the government’s policies towards the health needs of the country’s people. The collaboration we established with Abdi İbrahim within the scope of localization is a concrete step in this direction. We will continue to bring innovative treatments to Turkey by strengthening our existing collaborations. Thanks to these new treatments, we aim to change the course of serious diseases affecting patients in Turkey.

“WE WILL INCREASE COMPETITIVENESS OF TURKEY IN THE GLOBAL MARKET”

In his speech at the ceremony, Janssen Turkey General Manager Maria Fernanda Prado said the following regarding localization policies in Turkey: “We took action to improve Turkey’s domestic drug production capacity and competence and to increase its competitiveness in the global market. In our localization focus, our innovative drugs that will increase the international competitiveness of Turkey in the treatment of cancer and rare diseases will be included. I hope this new action we have taken will bring success”.

“WE TARGET TO BE AN ACTIVE PLAYER IN DOMESTIC DRUGS”

Speaking at the ceremony, CEO of Abdi İbrahim Süha Taşpolatoğlu stated that, as Abdi İbrahim, they are one of the biggest supporters of the localization in medicine and that they act with this responsibility in all of their ongoing investments as well as the investments they have implemented. Stating that they believe that localization is an extremely important driving force for Turkey to become a global player in medicine, Süha Taşpolatoğlu emphasized that they are proud to be the pioneer of this field both in intellectual stage and in practice and said:

“Abdi İbrahim, which has been operating in the pharmaceutical sector for 106 years, has a determined stance to run ahead with its technologically equipped facilities, strong human resources and investment in R&D but most importantly, our vision of supporting Turkey’s goal of becoming an active player in medicine. Our target in 2020 is to grow further in the field of production service with new collaborations and to become the production base of international companies in Turkey. For this purpose, we constantly strengthen our production infrastructure and offer our standards that compete with the world to the service of the companies we cooperate with. We work with the target of being the best option for all our customers with our production environments designed specifically for the needs. The production agreement we have with Janssen today for added value drugs is a natural result of this effort and is therefore extremely important to us. We consider this agreement, which we have signed, as the first step of our long-term collaboration, and we hope to further develop this collaboration in the coming period. In the coming period, we will continue to develop similar collaborations with the mission of being the driving force in Turkey’s growth targets.